People · Operator
Named in public records as an officer, director or promoter · active 2011–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| InCarda Therapeutics, Inc. | — | Pharmaceuticals | Series B | $66.3M | $857.5M | 2011 |
Carlos A. Schuler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carlos A. Schuler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Cheng | 1 | 9 |
| Alan Colowick | 1 | 7 |
| Andrew ElBardissi | 1 | 7 |
| Grace Colon | 1 | 4 |
| John S. Patton | 1 | 3 |
| Johan Christenson | 1 | 3 |
| Rangachari Narasimhan | 1 | 1 |
| Grace S. Colon | 1 | 1 |
| Dan Welch | 1 | 1 |
| Bischofberger Norbert | 1 | 1 |
| McCarthy Reenie | 1 | 1 |
| Miller Samantha | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.